PAT-505 is a selective, noncompetitive and orally available inhibitor of autotaxin(IC50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma).

PAT-505 is a potent, selective, noncompetitive inhibitor that displays significant inhibition of ATX activity in plasma and liver tissue after oral administration.?When dosed therapeutically in a Stelic Mouse Animal Model of nonalcoholic steatohepatitis (NASH), PAT-505 treatment resulted in a small but significant improvement in fibrosis with only minor improvements in hepatocellular ballooning and hepatic inflammation.

1782070-22-7

C23H18ClF2N3O2S

473.92

PAT-505

DMSO:48.33 mg/mL (101.98 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years